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Influence of vitamin 1) receptor genotype on bone mass changes after
renal transplantation. Renal transplant patients imniunosuppressed with
cyelosporine A (GsA) exhibit both a significant bone loss and an increased
rate of bone fractures. An association between common allelic variants of
the the vitamin D receptor (VDR) gene and hone mineral density and
turnover has been reported in adults. However, the genetic influence on
the rate of bone loss after renal transplantation has not been explored. We
prospectively determined the changes in spinal mineral density in 34
consecutive nondiahetic adults who received a eadaveric renal allograft.
Serum biochemical markers of bone metabolism and the vertebral mineral
density (VMD) assessed hy quantitative computed tomography were
determined at the time of transplantation and three and twelve months
later. In fifteen patients the histomorphometrie features of iliac bone were
analyzed at baseline and twelve months after transplantation. VDR alleles
were typed by a PCR assay based on a polymorphic Bsml restriction site.
Patients with the so-called "favorahie" bh genotype (N = 12) were
compared with those with the Bh or SB genotype (N = 22). Baseline
VMD was similar in patients with or without the favorable hb genotype.
Three months after transplantation the mean (± so) VMD decreased
14 13.3 percent in all patients (16.5 13.1% itt patients homozygous for
the h allele and 13.77 13.9% in those with Sb or BB genotypes). The
rate of VMD loss at this time inversely correlated with pretranspiant PTII
levels (r =
—0.40; P < (1.05). Between 3 and 12 months after transplan-
tation, patients with the favorable bb genotype recovered more VMD than
those with Bb or BB types and showed a significantly higher Z score at the
end of the follow-up (—t).37 1.16 vs. —1.10 1.20, respectively; P
0.05). The beneficial effect of hh genotype was independent of the
prevailing PTH levels and was also observed in those patients with a
baseline PTH level < 250 pg/mI (final Z score: hh, —0.42 1.3, N = 11:
BbIBB, —1.35 0.8, N = ii, P < 0.05). At the end of follow-up, the
histomorphometrie studies showed a higher bone formation rate adjusted
for PTH levels in patients with the Bb or SB genotype than in those with
the favorable bb genotype (0.29 0.06 vs. 0.21 0.118 gm3lgni2/day
respectively; P < 0.05). In conclusion, high pretranspiant PTH levels
enhance the early trabecular hone loss after renal transplantation, and
functionally different alleles of the vitamin D receptor gene may condition
the hone turnover and the degree of recovery of the bone mass.
Renal transplant patients immunosuppressed with cyclosporine
A (GsA) exhibit both a significant hone loss, which is mostly
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trabecular [11, and an increased rate of bone fractures ¶21. The
hone loss has been estimated to he 6.8% at the lumbar spine using
dual-photon absorptiometry during the first six months after
kidney grafting [lj. This mineral loss has been shown to start
within the first three months post-transplantation [3].
There are many factors involved in the pathogenesis of bone
loss after renal transplantation. The deleterious effect of glucocor-
ticoids on bone remodeling is considered a major factor [1,4] and,
depending on the level of renal function, chronic metabolic
acidosis could also have en effect 151 In addition, kidney trans-
plant recipients suffer from renal bone disease, and different
degrees of secondary hyperparathyroidism may be present before
renal transplantation [6, 7j. In fact, early bone loss after trans-
plantation at the lumbar spine has been associated with high
pretransplant PTH levels f 8, 9].
In normal individuals common allelic variants in the gene
encoding the vitamin D receptor (VDR) can be used to predict
differences in bone density and turnover, accounting for up to
75% of the total genetic effect on hone density [10, 11]. Moreover,
in three longitudinal studies the rate of bone loss in healthy
women [12, 13] and elderly subjects [14] was also predicted by the
VDR alleles. However, the genetic influence on the rate of bone
loss after renal transplantation has not been evaluated.
In the present prospective study we measured the changes in
spinal mineral density in 34 consecutive non-diabetic renal-
transplant recipients with different degrees of secondary hyper-
parathyroidism, from whom the genotype for the common allclic
variants of the VDR gene was determined. In order to study only
pure trahecular hone, axial mineral density was assessed by means
of quantitative computed tomography.
Methods
Patieni.c
From June 1990 to June 1991, 86 cadavcric renal transplants
were performed in the Regional Transplant Program of the
Hospital Universitario. We studied 34 consecutive recipients who
met the following criteria: they were followed in the transplant
clinic of the Hospital Universitario, were older than 18 years, had
no history of diabetes mellitus, and maintained a plasma creati-
nine < 2.3 mg/dl during the study follow-up. All had been on
maintenance dialysis before transplantation, seven of them were
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Age years
Sex (M/F)
Postmenopausal
Dialysis duration months
Cumulative steroids gr
3 months post-transplantation
12 months post-transplantation
Weight increase %
3 months post-transplantation
12 months post-transplantation
Body mass index kg/rn2
3 months post-transplantation
6 months post-transplantation
CsA levels ng/rnl
3 months post-transplantation
12 months post-transplantation
Serum creatinine mg/dl
3 months post-transplantation
12 months post-transplantation
Creatinine clearance mI/mm/i. 73 rn2
3 months post-transplantation
12 months post-transplantation
Total CO2 mEq/liter
3 months post-transplantation
12 months post-transplantation
Patients on furosemide %
"P < 0.01 vs. 3 months
b P < 0.05 vs. 3 months
bb
(N= 14)
Bb and BB
(N=20)
40.9 10.7
11/3
0/3
23.4 32.5
39 14.6
15/5
3/5
24.4 20.5
2.1 0.1
6.3 0.5"
2.4 0.9
6.3 1.5'
10±7is io.i0 7±713 10"
25.2 3.3
26 ii 3.3
25.86 2.9
26.9 3.1
290 88
168 53h
262 84.61
155.3 4h
1.2 0.3
1.24 0.3
1.4 0.5
1.45 0.4
85.7 28.7
79.4 29.7
79 23.4
81.7 27.9
23.5±4
25.7 2.4
4 (28.6%)
25±4
26.9 3.6
7 (35%)
receiving calcitriol, and none had been parathyroidectomized.
None of the patients received calcium supplements, vitamin D
derivatives, estrogens or anticonvulsants after grafting. The cause
of end-stage renal failure was chronic glomerulonephritis in 12,
policystic kidneys in 4, hypertensive nephropathy in 6, Alports
syndrome in 2, reflux nephropathy in 2, obstructive uropathy in 2,
and in 6 the cause was unknown. Immunosuppression consisted of
antilymphoblastic globuline (Merieux, Lyon, France) for induc-
tion and prednisone, cyclosporine, and azathioprine for mainte-
nance. Recipients older than 50 years did not received azathio-
prine. The dose of prednisone was 0.3 mg/kg body wt/day during
the first three months, and then was gradually reduced to 10
mg/day by one year. Cyclosporine was started when plasma
crcatinine was < 3 mg/dl at 8 mg/kg body wt/day, and then
adjusted according to the total blood levels [15]. The dose of
azathioprine was 1.25 to 1.50 mg/kg body wt. Episodes of acute
rejection were initially treated with three boluses of 500 mg of
intravenous methylprednisolone. Resistant episodes were treated
with a 10-day course of OKT3 (5 mg/day; Ortho Pharmaceutical,
NJ, USA). Table I summarizes clinical, immunosuppression, and
renal function data as a function of VDR alleles. Although the b
allele of the VDR gene has been shown to have a co-dominant
effect on bone density [101, no significant differences were found
between the Bb and BB individuals included in our study.
Consequently, patients with the "favorable" bb genotype were
compared to those with other genotype (Bb or BB).
The study was approved by the ethics committee at the Hospital
Universitario.
Study design
Biochemical markers of bone metabolism were measured be-
fore the dialysis session in preparation for surgery, and 3 and 12
months after transplantation. Vertebral mineral density was de-
termined during the first five days (3 2 days) after transplanta-
tion and 3 and 12 months later. Bone biopsy was performed in the
15 patients who consented to the procedure at the time of
transplantation and one year later.
Laboratoiy measurements
Serum calcium, albumin, phosphorus, and total alkaline phos-
phatase were measured with use of a computerized autoanalyzer
(Hitachi 717; Boehringer Manheim, Germany). The total serum
calcium was adjusted to albumin [16]. Serum concentrations of
intact PTH were determined by an IRMA assay (Nichols Institute,
San Juan Capistrano, CA, USA). Serum calcitriol levels were
measured by a cytoreceptor assay (Nichols Institute). Total blood
cyclosporine levels were quantified by FPIA assay using a mono-
clonal antibody (Abbot Laboratories, IL, USA). Osteocalcin, a
marker of bone turnover, was not determined in the present study
because its levels are influenced by glucocorticoids. In normal
individuals, glucocorticoids cause osteocalcin levels to fall within
24 hours [17].
Vertebral mineral density
The mean vertebral mineral density (VMD) of a representative
volume of pure trabecular bone of the T12-L3 vertebral bodies
was assessed by means of single energy quantitative computed
tomography (QCT) (Tomoscan 6 TX; Philips, Netherlands) as
described by Genant et al [18]. A solid phantom with five different
concentrations of hydroxyapatite and specific software (Image
Analysis, CA, USA) were used. A calibration was performed
before each determination. The results were expressed as the
number of SDS from the appropriate normal mean (Z score) using
the normative data base from UCSF [19].
Bone histomorphometty
Bone biopsies were performed in the 15 patients who consented
at transplantation and repeated one year later using a standard
technique described in our previous studies [7]. Briefly, a transil-
iac bone biopsy specimen was obtained with a 7 mm Bordier
trephine after in vivo double tetracycline labeling that was sepa-
rated by a 10 day interval. The bone specimen was obtained five
days after the second course of demeclocycline. Since all patients
received a cadaverie graft, in vivo tetracycline labeling could not
be performed at the time of transplantation. Undecalcified sec-
tions of trabecular bone were stained by the Masson-Goldner
method [7, 20] and the histologic stain for aluminum was per-
formed with the aurintricarboxylic acid method [211.
Genomic typing of VDR alleles
VDR alleles were typed by using a PCR-hascd assay developed
to ascertain the presence of a polymorphic BsmI restriction site
located in the seventh intron of the VDRgene. DNA was purified
from 3 ml of blood by standard proteinase K digestion, phenol-
chloroform extraction and ethanol precipitation [22]. To develop
a simple PCR-based assay, we cloned and sequenced a portion of
the VDR gene where the existence of a BsmI polymorphism had
been described [10]. Briefly, a 0.6 kh portion of intron 7 was
Table 1. Demographic and clinical data
Allele
I- -- a-a a — a — — — a
— — — — — — a a — —
a — — — — — — a —
Fig. 1. Polyactyalamide gel electrophoresis of a
PCR -amplified portion of human VDR intron 7
containing the polymotphic BsmI restriction site.
The 188 bp PCR product was subjected to
Bsml digestion, resulting in two fragments (111
and 77 bp) for the b allele, while the B allele,
which lacks the restriction site, remains as 188
bp. Lane 1 corresponds to a Bb individual, for
instance, while lane 2 is bb and lane 13 is BB.
Table 2. Biochemical indexes of bone and mineral metabolism at
baseline and at 3 and 12 months after grafting
Serum calcium total
Baseline
3 months post-transplantation
12 months post-transplantation
Serum phosphorus mg/dl
Baseline
3 months post-transplantation
12 months post-transplantation
PTH pg/mi
Baseline
3 months post-transplantation
12 months post-transplantation
Alkaline phosphatase U/liter
Baseline
3 months post-transplantation
12 months post-transplantation
Calcitriol pg/mi
3 months post-transplantation
12 months post-transplantation
Baseline aluminum gg/liter
Calciuria mg/dl GFR
3 months post-transplantation
12 months post-transplantation
Tubular reabsorption of phosphate %
3 months post-transplantation
12 months post-transplantation
ap <:0.01 and 5P <0.05 vs. bh
P < 0.01 and "P < 0.05 vs. baseline
P < 0.01 vs. 3 months
Normal values are: calcium, 9 to 10.5 mgldl; phosphorus, 2.2 to 4.4
mg/mI; alkaline phosphatase, 100 to 270 U/liter; PTH, 10 to 65 pg/mI;
calcitriol, 16 to 65 pg/mI.
Table 3. Vertebral mineral density in Z score (mean SD) before and
after 3 and 12 months of renal transplantation, as a function of VDR
alleles
Bb and
bh (N = 14) BB (N = 20)
(11 men, 3 women) (15 men, 5 women)
Baseline
Men 0.34 1.31 0.05 1.94
Women —0.09 1.95 0.9 2.43
All 0.25 1.39 0.26 2.04
3 Months after transplantation
Men —1 0.3 —1.14 1.46
Women —0.82 1.84 0.15 1.85
All —0.96 i.i6 —0.80 l.63
12 Months after transplantation
Men —0.51 082h —1.32 0.86"
Women 0.14 2.21 —0.43 1.87
All —0.37 116b —1.10 1.20°"
a p < 0.05 vs. bb
"P < 0.05 vs. baseline
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1 2 3 4 5 6 7 8 9 10 11 13
B (188bp)
111—
b
77—
Allele
bb Bb and BB
(N=14) (N=20)
9.3 0.6
9.4 :t 0.5"
9.3 0.7"
5 1.23 0.6
3.5 1°
194.3 264.4
98.2 64.4
77.1 39.2
189.5 174
179.9 44.1
197.3 68.8
25.3 17.9
31.6 11.2
31.6 24.8
9.4 0.7
9.91 0.9hc
9.8 0.9"°
5.6 1.4
3 0.8°
3.5 0.6°
362.1 440.2
169 196"
138 1233""
375.9 372.2
278.2 139.4
243.2 104.6
21 10.2
39.8 12.8""
39.8 12.8
0.07 0.04 0.19 t).13°
0.09 0.06 0.15 0.10"
77.2 10.1 67.4 22.4
72.8 10.4 75.1 10.7
BsmI restriction site (GAATGCG) was found within the ampli-
fied portion of intron 7, and the following primers were designed
to amplify a 191 bp fragment that includes the polymorphic BsmI
site: hVDR-3: 5'-AGTGTGCAGGCGAYTCGTAG-3' and
hVDR-4: 5' -ATAGGCAGAACCATCTCTCAG-3'. Approxi-
mately 0.1 jg DNA was amplified with primers hVDR-3 and
hVDR-4 in 50 jsl reactions including 10 mrvi Tris HCI, pH 9.0, 50
mM KCI, 1.5 ms MgCl2, 0.1% Triton X-100, 0.1 mrvi dNTPs, 0.5
/.LM each primer and 1 U Taq DNA polymerase. A Perkin-Elmer
480 thermal cycler was used to carry out 30 amplification cycles
with the following temperature profile: 94°C (1 miii), 62°C (1
mm), 72°C (1 mm). Ten microliters of the amplification product
were digested with SU BsmT (New England Biolabs) at 65°C
during three hours, in a total volume of 20 jsl, containing 4 mvi
sperm idine, 10 ms Tris HCI, pH 7.9, 50 mrvi NaCI, 10 mvi MgCI7,
0,1 mM DTT. Digestion products were resolved by electrophoresis
in 5% polyacrylamide gels, and, after staining with 0.5 sg/ml
amplified with primers hVDR-1: 5'-CAACCAAGACTACAAG-
TACCGCG-3' and hVDR-2: 5 -AACCAGCGGGAAGAGGT-
CAAGU-3'. The PCR product was cloned into pCRII (In Vitro-
gen) and sequenced with modified T7 DNA polymerase (USB). A
1.5
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0.5 0_b
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Fig. 2. Mean SEpercent and Z score changes of vertebral mineral density in al/patients and in male and female patients, as a function of VDR alleles.
Symbols are: ) bb allele; (A) Bb or BB alleles; * < 0.05.
ethidium bromide, the J7DR b allele was observed as two bands of
115 and 76 bp, while the B allele remained as a single 191 bp band
(Fig. 1). To validate our assay, we double-checked the VDR
typing of the patients included in this study by Southern analysis,
as described by Morrison et al [10], using a human VDR probe
obtained from the ATCC repository.
Statistical analysis
Friedman two-way ANOVA by ranks test was used to compare
OCT measurements at the timed study points. Paired compari-
sons between groups were performed by the Wilcoxon signed-
ranks test with adjusted degrees of freedom. Group mean values
were compared by the Mann-Whitney U test. Linear regression
analysis was used to compare changes in OCT measurements with
different clinical and biochemical parameters. The chi-square with
Yates correction and Fisher's exact tests were used to compare
proportions. By means of covariance analysis bone histomor-
phometry parameters were compared between the two genotype
Totres et al: Bone loss after renal transplantation
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Table 4. Bone histomorphometry before and after 12 months of transplantation
Pre-transplantation 12 Months post-transplantation
bb Bb or BB bb Bb or BB
(N=7) (N=8) (N=7) (N=8)
BV/TV % 21.64 6.30 27.90 7.60 20.40 50 23.90 2.40
OV/BV % 5.36 2.80 8 3.70 7.30 3.60 9 4.75
Fb.V/BV % 0.39 0.40 2.60 2.04 0.18 0.22 0.60 1
Ob.S/BS % 2.50 30 6.99 5.60 4.90 4.26 6.63 2.84
RS/BS % 7.20 13.90 12.50 8.50 14 14 15.50 11.50
Ocl/mm2 0.23 0.30 1.20 1.20 0.70 0.70 1 0.70
MAR p.m/day
BFR p.m3/pin2/day
—
— —
1.14 0.21
0.20 0.09
1.15 0.21
0.30 0.08'
PTHpg/ml 100 88 360 325 70.5 27 120 70
Abbreviations are: By/TV, trabecular bone volume/tissue volume (%); OV/BV, osteoid volume/bone volume (%); Fb.V/TV, fibrosis volume/tissue
volume (%); Ob.S/BS, osteoblast surface/bone surface (%); RS/BS, total resorptive surface/bone surface (%); Ocl/min2, number of osteoclast/mm2;
MAR, mineral aposition rate; BFR, bone formation rate.
ap < 0.05 vs. hh alleles
groups after adjusting for PTH levels. A P value less than 0.05 was
considered to be significant. Results are expressed as mean SD.
Results
All patients started full daily activities within two months after
transplantation. Regular menses resumed in the five premeno-
pausal women within two months after transplantation. No pa-
tient developed osteonecrosis or fractures. Table 1 shows demo-
graphic, clinical, and immunosuppression data. No differences
were observed between patients with or without the favorable
VDR genotype (bb). Biochemical data for mineral metabolism
are summarized in Table 2. As compared with patients with the
Bb or BB genotype, the bb genotype had significantly lower serum
and urinary calcium levels after 3 and 12 months of transplanta-
tion. Intact PTH levels were lower in the bb group, although
significant differences were demonstrated only 12 months after
grafting. At this time ealcitriol levels were also lower in the bb
group. Table 3 shows the vertebral mineral density (VMD) as a Z
score in both groups of patients. The baseline Z score was similar
in both groups of patients, and after three months of transplan-
tation a significant decrease in the Z score was seen in both
groups. However, between 3 and 12 months after transplantation,
patients with the favorable bb genotype recovered more VMD
than those without the allele, and they showed a significantly
higher Z score after 12 months of transplantation (Fig. 2). The
rate of bone loss in the first three months after transplantation
was significantly correlated with baseline PTH levels (Fig. 3);
however, no correlation was found between hone loss and weight
gain, cumulative steroids, or CsA levels. In fact, patients with a
baseline PTH level > 250 pglml, a value associated with signifi-
cant bone lesions of hyperparathyroidism [7], suffered a higher
bone loss after three months of renal transplantation than those
with PTH levels < 250 pg/mI (—21.08 10.29% vs. —11.05
13.81%, respectively, P < 0.05). Except for the influence of VDR
genotype, no correlation was found between the change in VMD
observed 3 to 12 months after transplantation and any other
parameter, including the PTH values at any time.
Table 4 shows quantitative histomorphometric indexes of 15
patients from whom bone biopsies were obtained at grafting and
12 months later. Patients with the bb genotype had lower PTH
levels, marrow fibrosis, osteoclast number and osteoblast surface
at baseline than those with other VDR genotypes, although
differences did not reach statistical significance. Twelve months
after transplantation a decrease in marrow fibrosis was seen in
both groups of patients although only in the non-bb group it
became statistically significant. A lower bone formation rate was
observed at this time in bb patients as compared with those with
other genotype. After adjusting for PTH levels, this difference
persisted (0.29 0.06 vs. 0.21 0.08 p.m3/jrm2/day, respectively;
P < 0.05). When both groups of patients were analyzed together,
a significant correlation between VMD loss and the bone forma-
tion rate was found (Fig. 4). After one year of transplantation, the
changes in VMD assessed by OCT were directly correlated with
those detected in trabecular bone volume by transiliac bone
biopsy (r = 0.81; P < 0.001).
Since patients with the bb allele tended to show lower PTI-I
levels than those with other genotypes throughout the study
period (Table 2), we analyzed the VMD changes of the subgroup
of patients with pretransplant PTH levels < 250 pg/mI. Table 5
shows that patients with or without the favorable hh genotype
were remarkably similar with respect to demographic, clinical, and
biochemical data. However, the recovery of VMD from 3 to 12
I
0.1 0.2 0.3 0.4
50
25
>
. 0 U0C) I...Il.
.
U.o —25
U
—50
BFR, p.m34tm2/day
Fig. 4. Correlation between the bone formation rate in the iliac crest biopsy
one year after transplantation and the rate of vertebral mineral density loss
during that period, in 15 patients (r = — 0.61; P < 0.01).
Discussion
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the study. Genotype frequencies were similar to those reported in
___________
Australian [10], American [23], and European population [24,251.
Trabecular bone has a higher turnover and is more sensitive to
metabolic changes than cortical bone [26]; as a result bone density
— -
changes after transplantation occur preferentially at this site [1, 3,
8]. Thus, we assessed vertebral mineral density (VMD) in pure
trabecular bone by means of quantitative computed tomography
(QCT) [18]. Our study shows that early bone loss after transplan-
tation is more severe when high pretransplant PTH levels are
present, and that the VDR genotype conditions the bone turnover
and the recovery of VMD one year after transplantation.
Our study confirms previous observations showing an early and
profound decrease in VMD after kidney grafting [1, 3, 8, 9]. The
observed mean decrease of VMD after three months in our study
(14%) was higher than the 5 to 10% reported by others [1, 3, 8].
This may be due to the fact that in those studies, bone density was
assessed by dual photon absorptiometry [1] or dual energy
radiography [3, 8], which measure an integral of trabecular and
cortical bone. It should be noted that trabecular bone accounts for
only 24% of the total vertebral mineral content [27]. Pacifici et al
[28] have demonstrated that OCT, which only measures trabecu-
lar bone, discriminates better than dual energy radiography
between normal and osteoporotic women. Similarly, Ott et al [29]
found that QCT was more sensitive than dual photon absorpti-
59.1 54 ometry in separating postmenopausal women with fractures from
72.1 22.6 a group without fractures. Alternatively, the larger VMD loss
68.2 37.6 detected in our study could be explained by a marrow-fat depen-
169.2 83 dent underestimation of VMD intrinsic to QCT [30]. Since the fat
198.3 75 content of the bone marrow is inversely related with the degree of
203.9 91.6 mineralization [28], the fat-dependent underestimation of the
26 1 ÷ 14 2 VMD is actually advantageous in that it amplifies the capability of408 163, OCT to detect bone demineralization. Nevertheless, the direct
correlation between changes in trabecular bone volume in the iliac
0.16 0.07 crest biopsy and VMD after transplantation suggests that OCT
0.13 0.06' accurately measured the bone mass changes in our study.
Of the many factors inherent to the process of transplantation
that we have considered, only the degree of pretransplant hyper-
parathyroidism was associated with the rate of bone loss over the
first three months after transplantation, as has been previously
reported [8, 9]. The increased number of bone remodeling units
induced by high PTH levels, is associated early after transplanta-
tion with the steroid-dependent inhibition of osteoblast function
[1, 31]. The ensuing imbalance between resorption and formation
may give rise to a rapid bone loss. Interestingly, patients with
pretransplant intact PTH levels > 250 pg/ml, which are associated
with significant hyperparathyroid bone disease [71, suffered a
VMD loss that is almost double than that of patients with
pretransplant PTH levels < 250 pg/mI. Thus, in order to prevent
excessive early bone loss after transplantation, dialysis patients
should be maintained with a PTH level below 250 pg/ml which still
is 4 times above the upper normal limit.
Among the many factors analyzed in our study, only the VDR
genotype predicted the recovery of the VMD between 3 and 12
months after transplantation. Although patients with the favor-
able bb genotype underwent transplantation with a similar Z score
than those with the Bb or BB genotype, they finished the study
with a significantly higher Z score (Fig. 2). The bone turnover at
this time, ascertained by the bone formation rate in the bone
biopsy, was significantly higher in the Bb or BB patients as
compared to those of the hh group (Table 4) and the bone
Table 5. Demographic, clinical, and biochemical data of 22 patients
with pre-transplant PTH levels <250 pg/mI
Bb and BB
(N= 11)
42.1 16.5
8M/3F
2
10.6 t.8
bb
(N = 11)
38.3 9.2
8M/3F
0
13.1 11
25.6 2.7
2.1 0.2
6.3 05d
1.2 0.3
22.3 3
2.7 1.2
6.3 1.8'
1.4 0.4
298.8 99.3 272 95.2
169.4 596' 150.4 191d
9 0.4
9.5 0.4"
9.4 0.6"
4.8 1.3
3.2 0.6"
3.7 0.5"
Age
Sex (M/F)
Postmenopausal
Weight increase %
12 months after transplantation
Body mass index kg/rn2
12 months after transplantation
Cumulative steroids gr
3 months post-transplantation
12 months post-transplantation
Serum creatinine rng/di
12 months post-transplantation
CsA levels ng/ml
3 months post-transplantation
12 months post-transplantation
Serum calcium rng/dl
Baseline
3 months post-transplantation
12 months post-transplantation
Serum phosphorus mg/dl
Baseline
3 months post-transplantation
t2 months post-transplantation
PTH pg/mi
Baseline
3 months post-transplantation
12 months post-transplantation
Alkaline phosphatase U/liter
Baseline
3 months post-transplantation
12 months post-transplantation
Calcitriol pg/mi
3 months post-transplantation
12 months post-transplantation
Calciuria mg/dl GFR
3 months post-transplantation
12 months post-transplantation
8.9 0.4
9.3 0.5"
9.2 0.6"
5 1.2
3 0.7"
3.6 1.1"
87.5 62
89.4 43.1
54.4 28
170 95
179.6 49
19t 75
25.3 19
27.9 9.3
0.08 0.04
0.08 0.05
"P < 0.01; hp < 0.05 vs. bb; "P < 0.05 vs. baseline; P < 0.01 vs. 3
months
Normal values are: calcium, 9—10.5 mg/dl; phosphorus, 2.2 to 4.4 mg/dl;
alkaline phosphatase, 100 to 270 U/liter; PTH, 10 to 65 pg/mI; calcitriol, 16
to 65 pg/mI.
months after transplantation and the final Z score, were signifi-
cantly higher in bb patients than in those with other genotype
(—0.42 1.3 vs. —1.35 0.8, respectively, P < 0.05; Fig. 5). When
excluding the two post-menopausal women, the effect of the VDR
genotype was still present (finalZscore: —0.38 0.73 vs. —1.16
1.39, respectively; P < 0.05).
Genetic factors, in association with a number of environmental
factors, are important determinants of the bone mass. Among
such heritable factors a major role has been attributed to the
vitamin D receptor (VDR) gene, for which two common alleles
have been described (B and h), based on a polymorphic BsmI site
(absent in B and present in b) [10]. We developed a FCR-RFLP
procedure to assess these alleles and investigated the prediction of
bone density changes after renal transplantation based on patient
genotype. To minimize coexistent abnormalities, we included only
nondiahetic patients with an acceptable renal function throughout
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formation rate was inversly correlated with the rate of VMD loss
over one year of transplantation (Fig. 4). This finding is in keeping
with the data of Morrison et al [101 who reported higher circu-
lating osteocalcin levels, a marker of bone turnover, in normal
individuals with the Bb or BB genotypes as compared with those
with the bb genotype. In the present study, however, the differ-
ences in bone turnover betwen this two groups after one year of
transplantation may have been influenced by the lower PTH levels
in the bb group (Table 2). If only patients without significant
hyperparathyroid bone disease at transplantation are considered
(PTH < 250 pg/mI), PTH levels after 12 months of transplanta-
tion were similar in the two groups (Table 5) and still the recovery
of VMD between 3 and 12 months of transplantation was
observed only in bb patients (Fig. 5). The lower urinary calcium
excretion despite similar calcium and PTH levels in bb patients
one year after transplantation, suggests that they were subjected
to a lower rate of bone resorption than patients with the Bb or BB
genotypes. Thus, the beneficial effect of bb genotype is indepen-
dent of the prevailing PTH levels.
The molecular mechanisms by which bone density and turnover
are regulated by the VDR gene are not certain and more studies
are needed to address the relationship between the BsmI poly-
morphism and the function of the VDR gene product. The
possibility exists that allelic differences in the 3' untranslated
region of the VDR gene may alter the transcriptional efficiency of
the gene or the stability of the transcribed mRNA [10]. The higher
circulating levels of calcitriol observed in BB women [10, 321 may
be an adaptative response to the altered VDR function. In the
present study serum calcitriol levels one year after transplantation
were also higher in the group with the Bh or BB genotype (Table
5) and this could contribute to the accelerating bone remodeling
and lower bone mineral density.
Although several studies performed on different populations
have reported a strong relationship between polymorphism at the
VDR gene and VMD [10—1 41, the results have not been uniform
and other studies have not found such a relationship [23—25].
Moreover, affirmative [33] and contrasting [34] views have been
recently reported. The fact that we found a significant association
between the VDR genotype and the VMD recovery between 3
and 12 months after transplantation suggests that, like in other
multifactorial diseases, the phenotypie expression is substantially
affected by environmental factors. Both some degree of persistent
hyperparathyroidism and cyclosporine A administration [35] have
been shown to estimulate bone turnover. Thus, the genetic
predisposition to achieve higher bone density linked to the VDR
genotype bb could become more evident in patients challenged to
lose bone mass as a consequence of renal transplantation. In
addition, a reduced calcium absorption efficiency on low calcium
intake in postmenopausal women with the BB genotype, consis-
tent with a functional defect in the intestinal VDR, has been
recently reported [361. Since corticosteroids decrease intestinal
calcium absorption [37] and no patient received calcium or
vitamin D supplements, this may be another factor contributing to
the influence of the VDR genotype in our study.
In conclusion, high pretransplant PTH levels enhance the
trabecular bone loss early after renal transplantation, whereas
functionally different alleles of the vitamin D receptor gene may
modulate the bone turnover and the degree of bone mass recovery
during the first year of renal transplantation. This findings may
have important implications in targeting prophylactic interven-
tions.
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